Clinical Trial Update: The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial investigating ticagrelor's effect on 15-epi-Lipoxin A4 and inflammation in atherosclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Atherosclerosis | Phase 4 | Status: WITHDRAWN